MIM
EUCRW

Monashee Investment Management’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Monashee Investment Management’s Portfolio EUCRW Stock Details EUCRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-99,998
Closed -$71K – 195
2021
Q3 		$71K Hold
99,998
– – 0.01% 189
2021
Q2 		$104K Hold
99,998
– – 0.01% 318
2021
Q1 		$125K Buy
+99,998
New +$162K 0.02% 279

Other funds holding EUCRW

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Monashee Investment Management's EUCRW Position: Q4 2021 in Review

Monashee Investment Management sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q4 2021, closing a stake of 99,998 shares — an estimated $71K sold.

Monashee Investment Management first reported a position in EUCRW in Q1 2021 and held it in 3 quarters. The position peaked at $125K in Q1 2021. 19 funds tracked by Wall St. Rank hold EUCRW as of Q4 2021.

  • Monashee Investment Management reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q4 2021 after selling out during the quarter.
  • Monashee Investment Management sold 99,998 Eucrates Biomedical Acquisition Corp. Warrant shares in Q4 2021, an estimated $71K.
  • Monashee Investment Management first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2021 and held it in 3 quarters.
  • Monashee Investment Management's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $125K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q4 2021.

Based on Monashee Investment Management's 13F filing for Q4 2021, filed 7 Feb 2022.